NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

TG Therapeutics, Inc. (TGTX) Stock Analysis

TG Therapeutics, Inc. (TGTX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

TGTX

$53.20

−$1.33 (−2.44%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TGTX with… →

TGTX Key Statistics

As of Oct 21, 2026
Trading
Open
$54.51
Previous Close
$54.53
Day's Range
52.73–54.95
52-Week Range
26.76–59.30
Volume
1.18M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.80
Valuation
Market Cap
$8.14B
P/E Ratio
19.35
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
19.65
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.61
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
10.19
EPS (ttm)Profit attributable to each share over the last twelve months.
2.75
Financials (FY)
Revenue (FY)
$616.29M+87.32%
Net Income (FY)
$447.18M+1,812.41%
Profit marginThe share of revenue left as profit after all costs and taxes.
55.22%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
153.08M
1-Year Return
+51.05%
Dividend and dates
Earnings Date
November 2, 2026estimated
Avg Volume
1.95M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, TGTX closed at $53.20, +51.05% over 1 year.

TG Therapeutics, Inc. (TGTX) has a market capitalization of $8.14B.

In fiscal 2025, TGTX reported revenue of $616.29M.

TGTX Stock Return by Calendar Year

TG Therapeutics, Inc. (TGTX) 10-year return: what $10,000 became

1 year
$10,000 $15,105
+51.05%
5 years
$10,000 $16,724
+67.24%
10 years
$10,000 $82,995
+729.95%

If you had invested $10,000 in TG Therapeutics, Inc. (TGTX) 10 years ago, at the close on October 21, 2016, it would have been worth $82,995 at the close on October 21, 2026: +729.95% in total, +23.57% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+78.46%
2025−0.96%
2024+76.23%
2023+44.38%
2022−37.74%
2021−63.48%
2020+368.65%
2019+170.73%
2018−50.00%
2017+76.34%
2016 (partial year)−16.22%

As of October 21, 2026.

TGTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$616.29M$447.18M72.6%
2024$329.00M$23.38M7.1%
2023$233.66M$12.67M5.4%
2022$2.79M−$223.81M−8,036.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$616.29M$515.57M$123.32M$447.18M72.6%
2024$329.00M$290.52M$41.93M$23.38M7.1%
2023$233.66M$219.53M$20.63M$12.67M5.4%
2022$2.79M$2.52M−$218.32M−$223.81M−8,036.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TGTX Valuation vs Biotechnology Median

Median of 608 stocks
MetricTGTXBiotechnology medianvs median
P/E19.3516.6017% above
P/S ratio10.1913.3023% below
Profit margin55.22%−38.31%93.5 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 15 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values TG Therapeutics, Inc. (TGTX) at $8.14B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 399.

The 52-week range on file runs from $26.76 to $59.30. TGTX last closed at $53.20 on October 21, 2026. That is −$1.33 (−2.44%) against the previous close. The latest close sits 98.8% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $616.29M. Against the prior fiscal year total of $329.00M, that is a change of +87.32%. Net income for the same year was $447.18M. That is +1,812.41% against the prior fiscal year. The reported profit margin is 55.22%. That is 93.5 percentage points above the Biotechnology median of −38.31%. Trailing earnings per share are 2.75.

Across the 4 fiscal years on file, revenue moves from $2.79M in 2022 to $616.29M in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 19.35. That is 16.57% above the Biotechnology median of 16.6. On forward earnings the ratio is 19.65. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.61. Measured against sales, the shares trade at 10.19 times revenue. On price-to-sales that is 23.41% below the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The reported beta is 1.8. Daily returns over the trailing 10 years annualize to a volatility of 86.3%. Over the trailing twelve months the total return is +51.05%. Across 10 years the annualized return works out at +23.57%.

Growth & Income

No dividend is on file for TGTX.

So far in 2026 the total return is +78.46%. The strongest complete calendar year on file is 2020 at +368.65%; the weakest is 2021 at −63.48%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

TG Therapeutics, Inc. (TGTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
TG Therapeutics, Inc. TGTX $8.14B 19.4
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. TG Therapeutics, Inc. trades at a P/E of 19.4.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About TG Therapeutics, Inc.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

Visit website →